Evaluation of the TRPM2 channel as a biomarker in breast cancer using public databases analysis

Bol Med Hosp Infant Mex. 2016 Nov-Dec;73(6):397-404. doi: 10.1016/j.bmhimx.2016.10.001. Epub 2016 Nov 30.

Abstract

Background: Breast cancer is one of the most common malignancies affecting women. Recent investigations have revealed a major role of ion channels in cancer. The transient receptor potential melastatin-2 (TRPM2) is a plasma membrane and lysosomal channel with important roles in cell migration and cell death in immune cells and tumor cells.

Methods: In this study, we investigated the prognostic value of TRPM2 channel in breast cancer, analyzing public databases compiled in Oncomine™ (Thermo Fisher, Ann Arbor, MI) and online Kaplan-Meier Plotter platforms.

Results: The results revealed that TRPM2 mRNA overexpression is significant in situ and invasive breast carcinoma compared to normal breast tissue. Furthermore, multi-gene validation using Oncomine™ showed that this channel is coexpressed with proteins related to cellular migration, transformation, and apoptosis. On the other hand, Kaplan-Meier analysis exhibited that low expression of TRPM2 could be used to predict poor outcome in ER- and HER2+ breast carcinoma patients.

Conclusions: TRPM2 is a promising biomarker for aggressiveness of breast cancer, and a potential target for the development of new therapies.

Keywords: Biomarcador; Biomarker; Breast cancer; Canal iónico; Cáncer de mama; Ion channel; Microarray; Microarreglo; TRPM2.